Aspaveli is indicated as monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia.1
Patient burden
Up to 85% of patients receiving C5i treatment do not achieve normal-like Hb levels3
Patient outcomes
Aspaveli empowers patients by minimising debilitating fatigue and improving physical and social functioning2,4
Self-administration
Aspaveli is the first subcutaneous treatment for PNH that can be self-administered to suit patients' lifestyles1
PP-20361